Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial

JAMA Ophthalmology

Volumn 138, Issue 8, 2020, Pages 835-842

  Jackson, Timothy L ^a   Soare, Cristina ^a   Petrarca, Caroline ^a   Simpson, Andrew ^a   Neffendorf, James E ^a   Petrarca, Robert ^a   Muldrew, Alyson ^b   Peto, Tunde ^c   Chakravarthy, Usha ^b   Membrey, Luke ^d   Haynes, Richard ^e   Costen, Mark ^f   Steel, David ^g,h   Desai, Riti ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

^d MAIDSTONE HOSPITAL   (United Kingdom)

^e BRISTOL EYE HOSPITAL   (United Kingdom)

^f HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^g SUNDERLAND EYE INFIRMARY   (United Kingdom)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; STRONTIUM; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRACHYTHERAPY; CATARACT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL OUTCOME; CLINICIAN; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG FATALITY; EPIMACULAR BRACHYTHERAPY; EYE; FOLLOW UP; FOVEAL THICKNESS; HUMAN; INTENTION TO TREAT ANALYSIS; LENS; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PARS PLANA VITRECTOMY; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA LUTEA; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; WET MACULAR DEGENERATION; CHRONIC DISEASE; CLINICAL TRIAL; FEMALE; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY; VITRECTOMY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BRACHYTHERAPY; CHOROIDAL NEOVASCULARIZATION; CHRONIC DISEASE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MALE; RADIOTHERAPY DOSAGE; RANIBIZUMAB; RETREATMENT; STRONTIUM RADIOISOTOPES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; WET MACULAR DEGENERATION;

EID: 85087874280     PISSN: 21686165     EISSN: 21686173     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2020.2309     Document Type: Article

References (25)

1. Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012; 96 (5): 752-756. doi: 10.1136/bjophthalmol-2011-301109 22329913
2. Wong WL, Su X, Li X, Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2 (2): e106-e116. doi: 10.1016/S2214-109X(13)70145-1 25104651
3. Rosenfeld PJ, Brown DM, Heier JS,; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355 (14): 1419-1431. doi: 10.1056/NEJMoa054481 17021318
4. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014; 121 (1): 193-201. doi: 10.1016/j.ophtha.2013.08.011 24084500
5. Holz FG, Bandello F, Gillies M,; LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013; 97 (9): 1161-1167. doi: 10.1136/bjophthalmol-2013-303232 23850682
6. Maguire MG, Martin DF, Ying GS,; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2016; 123 (8): 1751-1761. doi: 10.1016/j.ophtha.2016.03.045 27156698
7. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013; 120 (11): 2292-2299. doi: 10.1016/j.ophtha.2013.03.046 23642856
8. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014; 121 (5): 1092-1101. doi: 10.1016/j.ophtha.2013.11.031 24461586
9. Chakravarthy U, Houston RF, Archer DB. Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study. Br J Ophthalmol. 1993; 77 (5): 265-273. doi: 10.1136/bjo.77.5.265 8318462
10. Kirwan JF, Constable PH, Murdoch IE, Khaw PT. Beta irradiation: new uses for an old treatment: a review. Eye (Lond). 2003; 17 (2): 207-215. doi: 10.1038/sj.eye.6700306 12640408
11. Dugel PU, Petrarca R, Bennett M, Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results. Ophthalmology. 2012; 119 (7): 1425-1431. doi: 10.1016/j.ophtha.2012.01.014 22465819
12. Petrarca R, Dugel PU, Bennett M, Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results. Retina. 2014; 34 (5): 874-879. doi: 10.1097/IAE.0000000000000026 24169101
13. Jackson TL, Desai R, Simpson A,; Macular Epiretinal Brachytherapy versus Ranibizumab (Lucentis) Only Treatment (MERLOT) Study Group. Epimacular brachytherapy for previously treated neovascular age-related macular degeneration (MERLOT): a phase 3 randomized controlled trial. Ophthalmology. 2016; 123 (6): 1287-1296. doi: 10.1016/j.ophtha.2016.02.028 27086023
14. Dugel PU, Bebchuk JD, Nau J,; CABERNET Study Group. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology. 2013; 120 (2): 317-327. doi: 10.1016/j.ophtha.2012.07.068 23174399
15. Jackson TL, Dugel PU, Bebchuk JD,; CABERNET Study Group. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology. 2013; 120 (8): 1597-1603. doi: 10.1016/j.ophtha.2013.01.074 23490325
16. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310 (20): 2191-2194. doi: 10.1001/jama.2013.281053 24141714
17. MedDRA. Welcome to the ICH MedDRA website. Accessed June 1, 2020. https://www.meddra.org/how-to-use/support-documentation/english
18. Jackson TL, Chakravarthy U, Kaiser PK,; INTREPID Study Group. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology. 2013; 120 (9): 1893-1900. doi: 10.1016/j.ophtha.2013.02.016 23490327
19. Jackson TL, Chakravarthy U, Slakter JS,; INTREPID Study Group. Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study. Ophthalmology. 2015; 122 (1): 138-145. doi: 10.1016/j.ophtha.2014.07.043 25208859
20. Jackson TL, Shusterman EM, Arnoldussen M, Chell E, Wang K, Moshfeghi DM; INTREPID Study Group. Stereotactic radiotherapy for wet age-related macular degeneration (INTREPID): influence of baseline characteristics on clinical response. Retina. 2015; 35 (2): 194-204. doi: 10.1097/IAE.0000000000000283 25102198
21. Jackson TL, Donachie PH, Sparrow JM, Johnston RL. United Kingdom National Ophthalmology Database Study of Vitreoretinal Surgery: report 1; case mix, complications, and cataract. Eye (Lond). 2013; 27 (5): 644-651. doi: 10.1038/eye.2013.12 23449509
22. Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci. 2012; 53 (9): 5877-5880. doi: 10.1167/iovs.12-10164 22836776
23. Chen YY, Chen PY, Chen FT, Chen YJ, Wang JK. Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema. Int Ophthalmol. 2018; 38 (1): 293-299. doi: 10.1007/s10792-017-0462-1 28176171
24. Neffendorf JE, Desai R, Wang Y, StereoTactic radiotherapy for wet age-related macular degeneration (STAR): study protocol for a randomised controlled clinical trial. Trials. 2016; 17 (1): 560. doi: 10.1186/s13063-016-1676-7 27881184
25. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994; 308 (6921): 81-106. doi: 10.1136/bmj.308.6921.81 8298418